The history of antibiotics has repeated itself: drugs are discovered, but bacterial evolution can soon render them ineffective in treating infections. Resistance is fueled by injudicious use of existing drugs and compounded by a failure to develop novel new ones. Many major pharmaceutical companies have limited their investments in this antibiotic innovation, and only two new classes of these substances have reached the market in the past 30 years.
Pew’s work on antibiotics and innovation develops and supports policies that will spur innovation of new antibiotics to fight infections today and to ensure a healthy nation in the future.
Our WorkView All
On Sept. 18, the Obama administration took unprecedented action to combat antibiotic-resistant bacteria, a significant public health problem that claims 23,000 lives and causes 2 million infections in the U.S. each year. The administration released a national strategy and executive order, which were accompanied by a report from the President’s Council of Advisors for Science and... Read More
On September 19, Allan Coukell, senior director of drugs and medical devices testified, delivered testimony in front of the House Committee on Energy and Commerce Health Subcommittee at a hearing entitled “Examining Ways to Combat Antibiotic Resistance and Foster New Drug Development." Read More
The Obama administration laid out a national strategy today to stem the rising tide of antibiotic resistance, which threatens human health worldwide. The strategy provides an opportunity to bring together the resources of the federal government, agency-by-agency, to address this mounting crisis. Read More